chronic kidney disease

Showing 8 posts of 8 posts found.

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus

May 18, 2023
Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …

Bayer’s cardiovascular drug shows impressive Phase III results

May 11, 2021
Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …

Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …


Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …


China becomes first country to approve roxadustat in chronic kidney disease

December 19, 2018
Research and Development, Sales and Marketing AstraZeneca, China, chronic kidney disease, pharma

AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor …

Astellas’ chronic kidney drug shows superiority at Phase 3

September 20, 2018
Research and Development Astellas, chronic kidney disease, pharma, roxadustat

Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …


Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

March 30, 2016
Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …

Latest content